Promontory Therapeutics Inc. is a clinical stage pharmaceutical company developing small molecule immunotherapies. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death as well as osteotropism that confers advantages indealing with cancers that originate in or metastasize to the bone. Clinical data generated to date across three Phase 1 studies have demonstrated single-agent anti-cancer activity and an attractive tolerability proﬁle, and three Phase 2 studies of PT-112 are underway. The company also sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pﬁzer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada), and has an active collaborative research and development agreement (CRADA) with the NCI to conduct a Phase 2 trial utilizing PT-112 in thymic epithelial tumors.

Biotechnology

Pharmaceutical

Promontory Therapeutics

Matthew Price

Jesse Borgese

Tyler Ames

Marie-Therese Hehenberger

Mariam Mahbob, CCRP

Johan Baeck

Helene Shea

Elodie Benard, MS, CCRP-PM

Aamena Chaudhry

The Research and Development team at Promontory Therapeutics is responsible for the design, execution, and oversight of clinical trials for PT-112 and other pipeline candidates. They collaborate with external partners and regulatory bodies to ensure compliance and advance novel immunotherapy developments, while analyzing clinical data to support ongoing studies and inform future research directions. The team's expertise in oncology and immunology drives innovation and helps translate scientific findings into effective therapies for cancer patients.

Research and Development

Leadership Team

Clinical Operations

Research and Development

About

Team members

Other teams at Promontory Therapeutics

Leadership Team

Clinical Operations